ALKS compared with KYMR: revenue, margins and what each company keeps, and the suppliers and customers both name

ALKSAlkermes plc.

Mkt capRevenueRevenue

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ALKSAlkermes plc.

KYMRKymera Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALKS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.3%▲+1.78%×0.25

Q2 FY26±9.8%▼−4.23%×0.43

May 5 '26±7.3%▲+6.09%×0.84

Q1 FY26±8.6%▼−7.04%×0.81

KYMR

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±18.2%▲+0.07%×0.01

Q2 FY26±10.4%▲+1.04%×0.10

= impliedALKS realized, solidKYMR realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

Q1 FY26

±10.3%

▼−0.54%

×0.05

Feb 26 '26±11.8%▲+4.80%×0.41

ALKSAlkermes plc.

45.88▲+3.01%· post 45.88

Mkt cap$7.7BRevenue$480MQ3 FY26Revenue$1.5BFY25

KYMRKymera Therapeutics, Inc.

131.73▲+2.82%· post 131.73

ClosedNov 6 '26

Mkt cap$11.2BRevenue$65MQ2 FY26Revenue$39MFY25

Compare

ClosedNov 6 '26

ALKSAlkermes plc.

KYMRKymera Therapeutics, Inc.

45.88▲+3.01%post 45.88

Price

131.73▲+2.82%post 131.73

$7.7B

Mkt cap

$11.2B

Q3 FY26$480M

Revenue

$65MQ2 FY26

FY25$1.5B

Revenue

$39MFY25

ALKS45.88▲+3.01%vsKYMR131.73▲+2.82%ClosedNov 6 '26